These stocks have increased triple digits over the last three years.
The assumption may not be far from the demand for these companies now and later grows this decade.
10 shares we like more than Eli Lilly ›
What are monster stocks? In my book, it is a company that already provides huge growth to investors and, given the future opportunities, this player should continue to roar in the next year. Today, first and foremost, two shares are in line with this description, and they operate in the two highest growth industries: one is the leader of the weight loss drug market and the other dominates the artificial intelligence (AI) market.
Expected Goldman Sachs Research. And analysts predict that the AI market today will increase from billions of dollars to more than $ 2 trillion in the early 2030s. All of this means that these two monster stocks can apply to a whole new wave of growth – and they make great stocks that need to be kept for the next five years or even longer. Let’s look closely at each one.
Image Source: Getty Images.
Eli Lilly(NYS: LLY) Over the past three years, increased by more than 130%as customers have been blowing to their weight loss medicines. The company is commercialized by Tiurzepatide called Mounjar to obtain type 2 diabetes, and due to weight loss, but doctors have ordered or due to weight loss. Demand was high, sometimes even surpassed the supply and temporarily landed on Tyzepatide in the list of US Food and Drug Drug Lack of the US Food and Drug Administration.
Tyzepatide is now not on the list of deficiency, but demand remains high and has increased into the huge growth of Lilly. Mounjar and Zepbound both have become blockers, and in the last quarter they helped Pharma Giant report that income increased by $ 38% to $ 15 billion.
Lilly, of course, is not just a weight loss drug company and offers a wide drug portfolio in all therapeutic sites. However, the weight loss portfolio may be the driving force of the revenue growth and care results in the coming years. And what could offer a new impetus is possible confirmation of weight loss in the form of tablets (today’s drugs are injections). Lilly has recently completed successful clinical research on the ORFORGLIPON ORFORMS and is now preparing to apply for regulatory review.
Lilly leadership in weight loss drugs in the market has turned this pharmacy into monster shares, and both market growth and Lilly innovation should help maintain this impulse in the coming years.
When you think of ai giant, the first name that may come to mind is ai chips leader, Nvidia; But NVIDIA would not be where there is today, among other players, a company that turns NVIDIA design into reality. I speak Production of Taiwan semiconductors(NYSE: TSM)NVIDIA chips manufacturer, as well as chips of other market giants such as Advanced micro devices and Broadcom;
As a result, the benefits of the TSMC are not only about the success of the market leader, but also for the success of many other players. This makes the company excellent bet due to the rapidly growing AI area, especially today as companies increase the cost of AI infrastructure- Meta platforms and Alphabet published such messages with their latest profit calls. The TSMC will be useful as those players will rush to NVIDIA and other chip designers, and those designers need TSMC to make their own chips.
The TSMC has seen a preconceived for income over time, but it actually started as the Ai boom gained momentum.
Ycharts TSM Income (Annual) Data
Recently, the hen maker has expressed optimism about what will happen, saying that demand for companies and countries should be continued at a high level. It is also important to keep in mind that NVIDIA has committed to renewing its chips every year, which means that more growth for those chips manufacturer TSMC.
Another plus is that the TSMC invests $ 165 billion in US production – a step that can protect it from the effects of import rates and facilitate work with its US chips.
All of this means that investors are likely to be useful if they have these monster shares – one that has gained 200%over three years, as this new AI growth stage begins.
Before buying Eli Lilly, consider this:
Motley Fool Stock Advisor A team of analysts just found what they think is 10 best stocks Investors to buy now … and Eli Lilly was not one of them. 10 stocks that reduced the incision can return the monster in the coming years.
Consider when Netflix This list consisted of 2004. December 17th … If you have invested $ 1,000 during our recommendation, at our recommendation, You would have $ 681,260!* Or when Nvidia Made this list in 2005. April 15 … If you have invested $ 1,000 during our recommendation, at our recommendation, You should have $ 1,046 676!*
Now it is worth mentioning Share advisor The average return is 1 066%-S&P 500, compared to 186 percent. Share advisor;
See. 10 stocks »
*The stock advisor returns from 2025. September 8th
Adria Cimino has no position in any of the above shares. The Motley Fool has positions and recommends the production of advanced micro -equipment, alphabetical, Goldman Sachs Group, Meta platforms, Nvidia and Taiwan semiconductor. The Motley fool recommends Broadcom. The Motley fool has a disclosure policy.
2 monster shares to be considered for the next 5 years
